Stock TEVA TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 12:24:08 25/04/2024 BST 		5-day change 1st Jan Change
4,933 ILa +0.98% Intraday chart for Teva Pharmaceutical Industries Limited -0.90% +29.31%
04-22 Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court MT
04-19 Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets
AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
BU
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
AQ
Teva Pharmaceutical Industries : Immediate Report
PU
Teva Pharmaceutical Industries : Immediate Report
PU
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
BU
Teva enters into oncology biosimilar licensing agreement
AQ
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
BU
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
BU
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY Extended-Release Injectable Suspension at SIRS 2024
AQ
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
BU
TEVA Successfully Opposed Trademark AZILIDE
AQ
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
BU
Clinical Collaboration Agreement Established between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler Respiratory Program
AQ
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
BU
TEVA UK AND CLOSED LOOP MEDICINE ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE DEVELOPMENT OF PERSONALISED MEDICINES
AQ
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO in China
AQ
Alvotech and Teva Announce U.S. Approval of SIMLANDI injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira
AQ
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
BU
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. TEVA Stock
  5. News Teva Pharmaceutical Industries Limited
  6. Press Releases